Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $46.7 million.

  • Maravai Lifesciences Holdings' Operating Expenses fell 7640.31% to $46.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $464.3 million, marking a year-over-year increase of 433.64%. This contributed to the annual value of $494.8 million for FY2024, which is 5433.96% up from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Operating Expenses of $46.7 million as of Q3 2025, which was down 7640.31% from $113.7 million recorded in Q2 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Operating Expenses peaked at $208.0 million during Q4 2024, and registered a low of $46.7 million during Q3 2025.
  • Its 5-year average for Operating Expenses is $89.6 million, with a median of $80.5 million in 2023.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Operating Expenses soared by 25274.98% in 2021, and later tumbled by 7640.31% in 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Operating Expenses (Quarter) stood at $73.9 million in 2021, then rose by 29.18% to $95.5 million in 2022, then fell by 14.85% to $81.3 million in 2023, then skyrocketed by 155.83% to $208.0 million in 2024, then tumbled by 77.55% to $46.7 million in 2025.
  • Its last three reported values are $46.7 million in Q3 2025, $113.7 million for Q2 2025, and $96.0 million during Q1 2025.